Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype - PubMed (original) (raw)

. 1989 Nov;4(11):1363-74.

Affiliations

PMID: 2682463

Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype

A P Albino et al. Oncogene. 1989 Nov.

Abstract

This study examined noncultured and cultured melanomas and related precursor specimens for (i) mutated ras genes using polymerase chain reaction (PCR) methodology, (ii) correlation of mutated ras genes with differentiation related phenotypic characteristics, (iii) expression of ras-encoded p21 proteins in tissues by immunoperoxidase analysis, (iv) quantitative expression of mutated and wild-type ras encoded p21 proteins by flow cytometry, and (v) correlation between p21 expression, the occurrence of ras mutations, and cell cycle kinetics. The results of these studies are (1) 24% of cultured malignant melanomas have activated ras genes, with N-ras being activated ten times as frequently as Harvey (Ha)-ras. Each example of an activated ras gene showed a mutation at the 61st codon of the protein, with the exception of one melanoma which showed a mutation at codon 13 of the N-ras gene; (2) all the melanomas displaying an activated ras gene had a similar cell surface phenotype and appear to come from a similar phase of differentiation; (3) 5-6% of noncultured primary and metastatic melanomas have mutated ras genes; (4) no ras gene mutations were found in any precursor lesion, specifically normal nevi and dysplastic nevi; (5) immunoperoxidase analysis of paraffin-embedded specimens indicated no quantitative or qualitative alterations in p21 expression that correlate with tumor progression; (6) there were no observable differences in p21 expression between melanoma cells growing exponentially or in plateau phase, or between melanoma cells with or without ras mutations; nor were any cell kinetic differences found between cells with and without mutated ras genes. These studies suggest that the role of ras mutations may be limited to an indirect involvement in the transformation of a subset of melanomas.

PubMed Disclaimer

Cited by

AHNAK is downregulated in melanoma, predicts poor outcome, and may be required for the expression of functional cadherin-1.
Sheppard HM, Feisst V, Chen J, Print C, Dunbar PR. Sheppard HM, et al. Melanoma Res. 2016 Apr;26(2):108-16. doi: 10.1097/CMR.0000000000000228. Melanoma Res. 2016. PMID: 26672724 Free PMC article.
The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy.
Wu CP, V Ambudkar S. Wu CP, et al. Acta Pharm Sin B. 2014 Apr;4(2):105-11. doi: 10.1016/j.apsb.2013.12.001. Epub 2014 Jan 13. Acta Pharm Sin B. 2014. PMID: 26579371 Free PMC article. Review.
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility.
Marzagalli M, Montagnani Marelli M, Casati L, Fontana F, Moretti RM, Limonta P. Marzagalli M, et al. Front Endocrinol (Lausanne). 2016 Oct 26;7:140. doi: 10.3389/fendo.2016.00140. eCollection 2016. Front Endocrinol (Lausanne). 2016. PMID: 27833586 Free PMC article. Review.
Changes in protein expression during melanoma differentiation determined by computer analysis of 2-D gels.
Easty D, Hart IR, Patel K, Seymour C, Yacoub M, Domscheit A, Gunther S, Postel W, Gorg A, Dunn MJ. Easty D, et al. Clin Exp Metastasis. 1991 May-Jun;9(3):221-30. doi: 10.1007/BF01753726. Clin Exp Metastasis. 1991. PMID: 2060182
Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.
Platz A, Egyhazi S, Ringborg U, Hansson J. Platz A, et al. Mol Oncol. 2008 Apr;1(4):395-405. doi: 10.1016/j.molonc.2007.12.003. Epub 2007 Dec 28. Mol Oncol. 2008. PMID: 19383313 Free PMC article.

Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype - PubMed (original) (raw)